One Wealth Advisors LLC Has $205,000 Stake in Zymeworks Inc. (NYSE:ZYME)

One Wealth Advisors LLC lessened its position in Zymeworks Inc. (NYSE:ZYME) by 42.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,979 shares of the company’s stock after selling 10,366 shares during the quarter. One Wealth Advisors LLC’s holdings in Zymeworks were worth $205,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Zymeworks by 0.8% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,945,491 shares of the company’s stock worth $24,416,000 after purchasing an additional 14,604 shares during the period. State Street Corp lifted its holdings in shares of Zymeworks by 6.1% in the third quarter. State Street Corp now owns 1,171,777 shares of the company’s stock worth $14,706,000 after acquiring an additional 67,401 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Zymeworks by 127.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 715,632 shares of the company’s stock valued at $6,090,000 after acquiring an additional 401,068 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Zymeworks by 93.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company’s stock worth $9,403,000 after buying an additional 311,107 shares during the period. Finally, Vestal Point Capital LP grew its position in shares of Zymeworks by 39.8% in the 3rd quarter. Vestal Point Capital LP now owns 615,000 shares of the company’s stock valued at $7,718,000 after buying an additional 175,000 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Zymeworks Stock Performance

Shares of NYSE ZYME opened at $14.70 on Tuesday. The business has a 50-day simple moving average of $14.10 and a two-hundred day simple moving average of $13.06. Zymeworks Inc. has a 52 week low of $7.97 and a 52 week high of $17.70.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Leerink Partnrs raised Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a report on Monday, December 16th. Wells Fargo & Company raised their price target on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research report on Thursday, December 19th. Citigroup boosted their price objective on Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Finally, Leerink Partners raised shares of Zymeworks from a “market perform” rating to an “outperform” rating and increased their target price for the company from $10.00 to $25.00 in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $19.17.

Insider Buying and Selling at Zymeworks

In related news, Director Ecor1 Capital, Llc bought 11,958 shares of the company’s stock in a transaction that occurred on Tuesday, December 24th. The stock was bought at an average cost of $14.12 per share, for a total transaction of $168,846.96. Following the acquisition, the director now directly owns 14,704,239 shares of the company’s stock, valued at $207,623,854.68. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kenneth Galbraith sold 57,291 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $854,781.72. Following the completion of the transaction, the chief executive officer now owns 47,543 shares in the company, valued at $709,341.56. The trade was a 54.65 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders bought 603,539 shares of company stock valued at $8,384,708 and sold 89,601 shares valued at $1,336,847. Insiders own 1.92% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.